Is mogamulizumab-induced alopecia areata associated with favorable outcomes in Sézary syndrome?

Eur J Cancer. 2021 Oct:156 Suppl 1:S50-S51. doi: 10.1016/S0959-8049(21)00719-X.

Authors

Florent Amatore¹, Olivier Dereure², Emmanuel Delaporte¹, Caroline Ram-Wolff³, Martine Bagot³

Affiliations

¹ Department of Dermatology, Aix Marseille University, APHM, North Hospital, Marseille, France.
² Department of Dermatology, Montpellier University, Saint-Eloi Hospital, Montpellier, France.
³ Department of Dermatology, Paris University, Saint-Louis Hospital, AP-HP, Paris, France.

PMID: 34649661
DOI: 10.1016/S0959-8049(21)00719-X

No abstract available

Keywords: Mogamulizumab; alopecia areata; alopecia totalis; immune-related adverse event.